Health Canada has approved two generic versions of glucagon-like peptide-1 receptor agonist medication Ozempic, a move that could ease cost pressures for employer-sponsored benefits plans.

The introduction of generics is a key lever for controlling drug costs in both private and public plans, says Philippe Laplante, a principal at Eckler Ltd. “As a rule of thumb, as soon as one or two generics hit the market, their prices will be 20 to 30 per cent lower than the brand-name drug. Once two or........

© Benefits Canada